RedHill Could Soon Seek EUA For COVID-19 Therapy
Opaganib Shows Promise In Severe Sufferers
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
You may also be interested in...
The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.